共查询到20条相似文献,搜索用时 187 毫秒
1.
本文报告以羟基喜树碱为主治疗肝癌64例。其中单独使用19例,联合化疗45例。按全国通用肝癌疗效评定标准,本组完全缓解1例,部分缓解7例,稳定9例,有效率26.6%。中位生存期6个月。平均生存9.03月,半年生存率为46.9%,1年生存率为26.6%。联合化疗组的疗效较单独使用组为优。在与MMC、5-FU联合化疗的12例中,平均生存11.27月,一年生存率及有效率均为41.7%。表明羟基喜树碱治疗肝癌不仅疗效确切,而且与MMC、5-FU组合在某些不能使用强烈化疗如FAM、MFC方案治疗的中晚期肝癌又提供了一条新的化疗方案。 相似文献
2.
小剂量表阿霉素引起频发性室性早搏一例山东省阳谷县医院李泽锋,王秀霞患者女,33岁。心悸、胸闷1天,于1995年9月17日入院。1年前患乳腺癌行根治术,术后用CMF方案化疗3周期。1月前开始用CAF方案(CTX,表阿霉素,5-Fu)化疗2周期,共用表阿... 相似文献
3.
4.
5.
我科于1997年9月至1998年5月,应用美国百时美施贵宝公司生产的泰素联合化疗,治疗10例晚期癌患者,现将治疗结果报告如下。1材料与方法1.1临床资料10例中乳腺癌6例,均行根治术以后行辅助性放化疗后复发和(或)转移的患者,其中有2例在复发转移后曾用过ADM、CBP、CTX、5-FU联合化疗。卵巢癌4例行手术以后复发,其中3例用过PDD、5-FU、VP-16联合方案化疗2~3疗程,1例未用过化疗。10例病例的年龄27~60岁,中位48岁。1.2用药方法泰素联合CF或COF方案化疗,每次用量为C… 相似文献
6.
腹腔大容积化疗预防大肠癌术后腹腔及肝转移的研究 总被引:5,自引:0,他引:5
目的:研究腹腔大容积化疗预防大肠癌术后腹腔复发及肝转移的效果。方法自1995年6月-1999年12月将大肠癌术后患者分成2组:A组55例采用经埋藏式化疗泵行大容积腹腔化疗,B组43例行常规静脉化疗(CF/5-Fu方案),比较两者术后肝及腹腔复发的发生率、发生时间及术后存活时间。结果A组55例中,有2例于术后9、15个空复发,2例于术后13、16个月出现肝转移,发生率为8.3%,51例(92.7%) 相似文献
7.
低剂量粒—巨噬细胞集落刺激因子在肺癌化疗中的应用 总被引:2,自引:0,他引:2
31例肺癌患者大剂量化疗40例次,采用配对法分成加用低剂量粒-巨噬细胞集落刺激因子(GM-CSF)的治疗组及不加用的对照组(二组均为20例次)。结果表明,低剂量GM-CSF明显缩短化疗所致白细胞低下的时间:治疗组为14.5±9.49天,对照组为19.4±8.85天(P=0.02),同时提高白细胞下降最低值:治疗组为3.35×109/L±1.37×109/L,对照组为2.9×109/L±1.18×109/L。低剂量GM-CSF的主要不良反应为发热(80%)及肌痛、骨痛(10%)。结果提示:低剂量GM-CSF能支持癌症患者的大剂量化疗及连续化疗 相似文献
8.
动脉灌注化疗药物及LAK/IL—2治疗晚期贲门癌 总被引:1,自引:0,他引:1
为观察经皮动脉灌注化疗药物及LAK/IL-2治疗晚期贲门癌的疗效,采用经皮穿刺胃左动脉插管灌注健康人外周血LAK细胞1×108/L及IL-230万U,化疗药物为表阿霉素30mg、卡铂300mg、长春地辛(西艾克)4mg或5-Fu1000mg,每3周~4周一次,2次为一疗程,结果:经病理学确诊的共78例晚期贲门癌患者经此法共介入灌注146次,最多者5次,最少者1次,胃部病灶CR+PR占61.5%,生存最长41个月,最短4个月,中位生存期9.5个月,半年生存率为76.9%,1年生存率为30.8%,提示采用肿瘤供血动脉进行区域性灌注生物制剂及化疗药物,对于失去手术机会的晚期贲门癌病人不失为可供选择的有效治疗手段。 相似文献
9.
我院对18例进展期直肠癌进行了氟脲嘧啶(5-Fu)联合大剂量醛氢叶酸(CF)化疗合并同步放疗的临床研究。CF200mg/日,5-Fu375mg/m2/日静脉滴注,每日一次连用5天为一疗程。放疗与化疗同步,体外照射全盆腔DT50Gy/25次/5周,直肠腔内高剂量率放疗D5-20Gy/3-4次/2周。近期疗效完全缓解(CR)5例,部分缓解(PR)10例,好转(MR)3例。有效率83.34%。中位效应持续时间14个月。CF/5-Fu合并同步放疗是治疗进展期直肠癌的有效方法,近期反应及并发症尚在进一步观察中。 相似文献
10.
10例小儿恶性肿瘤病人在接受强化疗后给予G-CSF5-10ug/kg/d。9/10例平均4天,1/10例在14天时白细胞总数上升至5.0×10 ̄9/L以上,全部病例在停G-CSF后48~72小时时出现第二次血象下跌。并观察到6/10例在G-CSF后平均第5天外周血出现幼稚细胞,3/7例骨髓粒系原始+幼稚细胞不同程度升高,分别为20%、26%、8%,停用G-CSF一周后未经任何化疗自然恢复正常,提示这些原始细胞来自正常的造血干细胞。 相似文献
11.
Tomiyama J Kudo H Nakamura N Murai Y Tsunadori S Muto Y Urabe A Mori M Tsuruoka N Shirai T Kawado M Adachi Y Shirakura T Yamaguchi H Katsunuma H 《Oncology reports》1995,2(4):669-673
From January 1989 until December 1992, 120 elderly patients over 65 years old with multiple myeloma (MM) were enrolled with the Elderly Hematology Study Group (EHSG) with 14 institutions participating. Several courses of chemotherapy were conducted in 103 of the 120 patients, 33 patients with alpha-interferon (IFN) and 70 patients without IFN. The response rate (CR+PR) was 24.0% of all 120 cases, 24.2% of the group treated with IFN and 25.7% of those treated without IFN. Similarly, the efficacy rate (CR+PR+MR) of these groups were 78.8%, 81.8% and 78.8%, respectively. The 50% survival time was 31 months in the 120 cases as a whole, 44 months in the group treated with IFN and 38 months in the group treated without IFN. No significant difference was observed either in response rate (p=0.243) or survival time (p=0.262) in the groups treated with or without IFN. 相似文献
12.
13.
目的:观察吉西他滨+顺铂(GP)方案和氟尿嘧啶+顺铂(FP)方案治疗晚期复发转移性鼻咽癌的疗效及不良反应。方法:选择放疗后复发转移性鼻咽癌60例,分别采用GP方案或FP方案静脉化疗,21天为1周期。结果:GP组:CR5例、PR19例,有效率(CR+PR)80%;FP组:CR2例、PR14例,有效率(CR+PR)53.3%两组有效率有显著差异(P=0.0283)。中位PFS(无进展生存期)GP组8个月,FP组3个月(P=0.0001)。中位OS期(总生存期)GP组11个月,FP组7个月(P=0.0002)。两组毒性均能耐受。结论:GP方案较FP可以更好改善复发转移性鼻咽癌的RR、PFS和OS。 相似文献
14.
Twenty five cases of advanced postmenopausal breast cancer patients were treated with bisbromoacetyl hexestrol 3 CR and 5 PR were achieved. The response rate was 32%, and the average duration of remission 6 months. Vaginal bleeding was seen in 9 cases, 4 of whom were compelled to discontinue treatment. 相似文献
15.
本文报道了静脉用大剂量20%甘露醇(10me/kg)加大剂量BCNU(卡氮芥)(15mg/kg—45mg/kg)治疗非手术肺癌多发脑转移14例,收得了3例CR、5例PR、近斯缓解率(RR)57%(8/14)、中位生存期8个月的临床效果。 相似文献
16.
The Therapy of Primary Adult Systemic CD30-Positive Anaplastic Large Cell Lymphoma: Results of 40 Cases Treated in a Single Center 总被引:2,自引:0,他引:2
Renato Fanin Alessandra Sperotto Federico Silvestri Michela Cerno Antonella Geromin Raffaella Stocchi Laura Infanti Francesca Patriarca Francesco Zaja Daniela Damiani Michele Baccarani 《Leukemia & lymphoma》1999,35(1):159-169
The outcome of a series of adult patients, affected by primary systemic CD30-positive ana-plastic large cell lymphoma (ALCL), treated with a sequential intensive therapeutic program, has been analyzed and all data available in the literature have been reviewed. Forty consecutive, unselected patients with ALCL were treated with the F-MACHOP regimen, followed by radiotherapy (RT) for residual mediastinal disease (15 cases) and by autologous stem cell transplantation (ASCT) conditioned with BAVC (29 cases). Eighty-nine percent (32/36) of the patients younger than 60 years were eligible for completing the sequential treatment. Since then, 3 patients in CR refused ASCT, 1 was excluded for cardiac toxicity and 3 progressed and died of disease. Thus, 29 have been so far submitted to the transplant procedure. CR and PR rates were 40% and 45% respectively after CHT; 52.5% and 35% after RT; 80% and 5% after ASCT, with 78% of patients transplanted in PR convertin to a CR. Actuarial overall survival is 85% at 48.5 months (93% at 66 months for the 29 transplanted patients) and disease free survival is 100% at 54 and 64 months respectively, with no relapses observed among patients who reached a CR.
Considering our data and those of the literature, it can be concluded that although the role of ASCT in the therapy of ALCL must not be considered as definitive, its efficacy in converting PR into CR and in preventing relapses, suggests that a randomized trial comparing CHT alone vs CHT+ASCT should be undertaken. 相似文献
Considering our data and those of the literature, it can be concluded that although the role of ASCT in the therapy of ALCL must not be considered as definitive, its efficacy in converting PR into CR and in preventing relapses, suggests that a randomized trial comparing CHT alone vs CHT+ASCT should be undertaken. 相似文献
17.
R Fanin A Sperotto F Silvestri M Cerno A Geromin R Stocchi L Infanti F Patriarca F Zaja D Damiani M Baccarani 《Leukemia & lymphoma》1999,35(1-2):159-169
The outcome of a series of adult patients, affected by primary systemic CD30-positive anaplastic large cell lymphoma (ALCL), treated with a sequential intensive therapeutic program, has been analyzed and all data available in the literature have been reviewed. Forty consecutive, unselected patients with ALCL were treated with the F-MACHOP regimen, followed by radiotherapy (RT) for residual mediastinal disease (15 cases) and by autologous stem cell transplantation (ASCT) conditioned with BAVC (29 cases). Eighty-nine percent (32/36) of the patients younger than 60 years were eligible for completing the sequential treatment. Since then, 3 patients in CR refused ASCT, 1 was excluded for cardiac toxicity and 3 progressed and died of disease. Thus, 29 have been so far submitted to the transplant procedure. CR and PR rates were 40% and 45% respectively after CHT; 52.5% and 35% after RT; 80% and 5% after ASCT, with 78% of patients transplanted in PR convertin to a CR. Actuarial overall survival is 85% at 48.5 months (93% at 66 months for the 29 transplanted patients) and disease free survival is 100% at 54 and 64 months respectively, with no relapses observed among patients who reached a CR. Considering our data and those of the literature, it can be concluded that although the role of ASCT in the therapy of ALCL must not be considered as definitive, its efficacy in converting PR into CR and in preventing relapses, suggests that a randomized trial comparing CHT alone vs CHT+ASCT should be undertaken. 相似文献
18.
目的:观察DCF方案治疗局部进展期或转移性胃癌的疗效和不良反应。方法:自2007年10月至2009年8月,42例晚期胃癌患者采用DCF,DXT(多西紫杉醇)75mg/m2,静脉滴注,第1天;DDP(顺铂)25 mg/m2,第1-3天;CF(亚叶酸钙)200mg/d,静脉滴注2小时,第1-5天;5-FU(氟尿嘧啶)500mg/m2,第1-5天,静脉滴注5-6小时,3周为1周期,方案治疗,按WHO标准评价近期疗效和不良反应,随访疾病进展时间(TTP)和中位生存期(MST)。结果:全组42例均可评价疗效,其中CR 3例,PR 19例,SD 11例,PD 9例。有效率(RR)为54.7%,中位TTP为5.5个月,中位MST为10个月。不良反应主要是骨髓抑制及胃肠道反应,其次为口腔黏膜炎、腹泻及周围神经毒性。结论:DCF方案治疗晚期胃癌的疗效较好,不良反应可以耐受。 相似文献
19.
目的 探讨As2 O3 对APL病人的获得性耐药或内在性耐药。方法 86 例用As2 O3 巩固治疗的APL病人在第1次CR后3 a内复发的23例,20 例继续使用As2O3 ,3 例加用HA 或DA 方案。结果 23 例复发病人中15例又获CR,1例PR,7 例NR,这7 例中3 例应用As2O3 8 周后改用HA或DA而达CR,4例1 周内死亡。结论 初治的130 例中7 例NR可能存在内在性耐药,复发的23 例中也有7 例表现为耐药性,可能是获得性耐药,而不是多药耐药,所以与ATRA等无交叉耐药,提示As2O3 的耐药不是单一机制可以解释的。 相似文献
20.
J Yoshimoto Y Nasu T Akagi T Obama T Tsushima Y Ozaki Y Matsumura H Ohmori T Asahi K Ohkita 《Gan to kagaku ryoho. Cancer & chemotherapy》1985,12(6):1312-1317
A combined chemotherapy with cisplatin, ifosfamide and adriamycin (CIA therapy) was performed in 20 patients with advanced transitional cell carcinoma of the urinary tract. Adriamycin 30mg/m2 and ifosfamide 1.5g/m2 were administered on day 1 and cisplatin 50 mg/m2 on day 2, which was repeated at intervals of 3 weeks, in principle. According to Koyama and Saito's response criteria, complete response (CR), partial response (PR) and minor response (MR) were obtained in 1, 4 and 5 cases, respectively; CR+PR+MR in 10 cases out of 18 evaluable cases (56%). The duration of response was 2 to 14 months (median; 4 months) in the cases with CR and PR. The survival time of the responders ranged from 3 to 23 months (median; 11 months), being significantly longer than that of the non-responders (p less than 0.05, Generalized Wilcoxon test). Adverse reactions observed were of a slight or moderate degree, with only a few cases of damage to renal function. 相似文献